2-bromo-2-(pyridin-2-yl)-acetic acid | 52800-40-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-bromo-2-(pyridin-2-yl)-acetic acid
• 英文别名: 2-bromo-2-(2-pyridyl)-acetic acid；Bromo(pyridin-2-yl)acetic acid；2-bromo-2-pyridin-2-ylacetic acid
• CAS: 52800-40-5
• 化学式: C₇H₆BrNO₂
• 分子量: 216.034
• InChiKey: OCJKXTKMAMFNJF-UHFFFAOYSA-N

物化性质

• 沸点：
  302.7±27.0 °C(Predicted)
• 密度：
  1.741±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-bromo-2-(pyridin-2-yl)-acetic acid 、 2-羟基苯氧基乙酸 在 sodium hydroxide 作用下， 生成 2-(2-Pyridyl)-2-(2-carboxymethoxyphenoxy)-acetic acid
  参考文献：
  名称：

  3-Hydroxy-3-(1,2,5-thiadiazolyloxyalkanol)-3,4-dihydro-2H-1,5-ben

  摘要：

  描述了具有β-肾上腺素激动性能的3-羟基-3-(取代氨基烷基-3,4-二氢-2H-1,5-苯并二氧杂环己啶产品，因此适用于用作支气管扩张剂。这些产品基本上是通过从3-氧代-3,4-二氢-2H-1,5-苯并二氧杂环己啶制备的四种主要途径而制备的。通过一种途径，3-氧代苯并二氧杂环己啶与硝基烷烃反应，得到一种3-羟基-3-硝基烷基苯并二氧杂环己啶，其硝基被还原为胺，然后将所得化合物在加氢条件下与醛或酮反应，将期望的取代基引入氨基功能中。通过第二种途径，3-氧代苯并二氧杂环己啶与碱金属腈反应形成氰水合物，还原后形成3-羟基-3-氨基烷基苯并二氧杂环己啶，可以用酮或醛处理以得到期望的产物，也可以与亚硝酸钠或其他试剂反应形成3-螺苯并二氧杂环己啶-2-环氧烷，后者与胺反应提供所需的产物。3-螺苯并二氧杂环己啶-2'-环氧烷也可以通过将3-氧代苯并二氧杂环己啶与磺酰亚砜处理而获得，第四种方法涉及形成苯并二氧杂环己啶-3-螺-5'-噁唑烷-2'-酮，后者在稀碱处理后给出所需的3-羟基-3-(取代氨基烷基)-3,4-二氢-2H-1,5-苯并二氧杂环己啶。如果需要，可以用各种试剂处理这些中间噁唑烷酮化合物，以在起始物质的苯环部分上连接取代基。这些噁唑烷酮表现出β-激动和骨骼肌松弛性能。

  公开号：

  US03944560A1

文献信息

• N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR
  申请人：Glaxo Group Limited

  公开号：EP2167466A1

  公开（公告）日：2010-03-31
• US3944560A
  申请人：——

  公开号：US3944560A

  公开（公告）日：1976-03-16
• [EN] N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR<br/>[FR] HYDRAZIDES N-PHÉNYLE COMME MODULATEURS DU RÉCEPTEUR DE LA GRÉHLINE
  申请人：GLAXO GROUP LTD

  公开号：WO2008148853A1

  公开（公告）日：2008-12-11

  [EN] The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein: each R1 is independently selected from the group consisting of Cl, Br, CH3 and CF3; X is carbon or nitrogen; R1a is H or a straight C1-3 alkyl group; R2a is H or a methyl group R2 is selected from the group consisting of C1-3alkyl, H and -(CH2)n-, wherein n is 3 or 4 and the terminal carbon of the chain is bonded to the carbon atom adjacent to the nitrogen bearing the R2 group, such that a fused 6,5 or 6,6-bicyclic ring is formed. Y is selected from the group consisting of: phenyl which may be unsubstituted or substituted by one or more substituents independently selected from the group consisting of C1-3alkyl, C1-3alkoxy, halogen, C1-3alkyl substituted by 1 to 7 fluoro atoms and C1-3alkoxy substituted by 1 to 7 fluoro atoms; pyridyl which may be unsubstituted or substituted by one or more substituents independently selected from the group consisting of C1-3alkyl, OCH3, CF3, CN, and halogen; naphthyl which may be unsubstituted or substituted by one or more substituents independently selected from the group consisting of F and OCH3; pyrimidinyl; imidazo[1,2-a]pyridine-6-yl; benzothiophen-2-yl; benzothiophen-5-yl; benzofuran-2-yl; dibenzo[b,d]furan-3-yl; dibenzo[b,d]thiophen-2-yl; dibenzo[b,d]thiophen-4-yl; 1,3- benzodioxol-5-yl; 2,3-dihydro-1,4-benzodioxin-5-yl; 2,3-dihydro-1,4-benzodioxin-6-yl; 2,3- dihydro-1-benzofuran-4-yl; 2,2-difluoro-1,3-benzodiox-4-yl; pyridazinyl; imidazolyl; oxazolyl; pyrazolyl; thiazolyl; and triazolyl; with the proviso that when Y is 2,3-dihydro-1,4-benzodioxin-6-yl, R1 is not Cl; processes for their preparation, intermediates useble in these processes, pharmaceutical compositions containing them and their use in therapy, for example as modulators of of the growth hormone secretagogue receptor (also referred to as the ghrelin receptor or GHSR1a receptor) and/or for the treatment and/or prophylaxis of a disorder mediated by the ghrelin receptor.
  [FR] L'invention concerne de nouveaux composés de formule (I) ou un sel ou un solvate pharmaceutiquement acceptable de ceux-ci, dans laquelle R1 est indépendamment sélectionné dans le groupe formé de Cl, Br, CH3 et CF3; X représente carbone ou azote; R1a représente H ou un groupe alkyle C1-3 linéaire; R2a représente H ou un groupe méthyle R2 est sélectionné dans le groupe formé d'alkyle C1-3,
• 3-Hydroxy-3-(1,2,5-thiadiazolyloxyalkanol)-3,4-dihydro-2H-1,5-ben
  申请人：Merck & Co., Inc.

  公开号：US03944560A1

  公开（公告）日：1976-03-16

  3-Hydroxy-3-(substituted-aminoalkyl-3,4-dihydro-2H-1,5-benzodioxepin products are described that exhibit .sym.-advenergic stimulating properties and are therefore suitable for use as bronchodilating agents. The products are prepared essentially by four principal routes from 3-oxo-3,4-dihydro-2H-1,5-benzodioxepins. By one route the 3-oxobenzodioxepin is treated with a nitroalkane to give a 3-hydroxy-3-nitroalkyl-benzodioxepin the nitro group of which is reduced to an amine and the resulting compound reacted with an aldehyde or ketone under hydrogenating conditions to introduce the desired substituent into the amino function. By a second route the 3-oxobenzodioxepin is reacted with an alkali metal nitrile to form the cyanhydrin which upon reduction forms the 3-hydroxy-3-aminoalkyl-benzodioxepin that can be treated with a ketone or aldehyde to give the desired products or can be reacted with sodium nitrite or other agent to form a 3-spiro-benzodioxepin-2-oxirane which upon reaction with an amine provides the desired product. The 3-spiro-benzodioxepin-2'-oxirane also can be obtained by treatment of the 3-oxo-benzodioxepin with a sulfurylide, A fourth method involves forming a benzodioxepin-3-spiro-5'-oxazolidin-2'-one which upon treatment with dilute alkali gives the desired 3-hydroxy-3-(substituted aminoalkyl)-3,4-dihydro-2H-1,5-benzodioxepin The intermediate oxazolidinone compounds can be treated if desired with various agents to attach substituents on the benzenoid moiety of the starting substance. These oxazolidinones exhibit .beta. -stimulating and skeletal muscle relaxant properties.

  描述了具有β-肾上腺素激动性能的3-羟基-3-(取代氨基烷基-3,4-二氢-2H-1,5-苯并二氧杂环己啶产品，因此适用于用作支气管扩张剂。这些产品基本上是通过从3-氧代-3,4-二氢-2H-1,5-苯并二氧杂环己啶制备的四种主要途径而制备的。通过一种途径，3-氧代苯并二氧杂环己啶与硝基烷烃反应，得到一种3-羟基-3-硝基烷基苯并二氧杂环己啶，其硝基被还原为胺，然后将所得化合物在加氢条件下与醛或酮反应，将期望的取代基引入氨基功能中。通过第二种途径，3-氧代苯并二氧杂环己啶与碱金属腈反应形成氰水合物，还原后形成3-羟基-3-氨基烷基苯并二氧杂环己啶，可以用酮或醛处理以得到期望的产物，也可以与亚硝酸钠或其他试剂反应形成3-螺苯并二氧杂环己啶-2-环氧烷，后者与胺反应提供所需的产物。3-螺苯并二氧杂环己啶-2'-环氧烷也可以通过将3-氧代苯并二氧杂环己啶与磺酰亚砜处理而获得，第四种方法涉及形成苯并二氧杂环己啶-3-螺-5'-噁唑烷-2'-酮，后者在稀碱处理后给出所需的3-羟基-3-(取代氨基烷基)-3,4-二氢-2H-1,5-苯并二氧杂环己啶。如果需要，可以用各种试剂处理这些中间噁唑烷酮化合物，以在起始物质的苯环部分上连接取代基。这些噁唑烷酮表现出β-激动和骨骼肌松弛性能。